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Abstract
ABC transporters use the energy from binding and hydrolysis of ATP to import or extrude substrates across the membrane.
Using ribosome display, we raised designed ankyrin repeat proteins (DARPins) against detergent solubilized LmrCD, a
heterodimeric multidrug ABC exporter from Lactococcus lactis. Several target-specific DARPin binders were identified that
bind to at least three distinct, partially overlapping epitopes on LmrD in detergent solution as well as in native membranes.
Remarkably, functional screening of the LmrCD-specific DARPin pools in L. lactis revealed three homologous DARPins which,
when generated in LmrCD-expressing cells, strongly activated LmrCD-mediated drug transport. As LmrCD expression in the
cell membrane was unaltered upon the co-expression of activator DARPins, the activation is suggested to occur at the level
of LmrCD activity. Consistent with this, purified activator DARPins were found to stimulate the ATPase activity of LmrCD
in vitro when reconstituted in proteoliposomes. This study suggests that membrane transporters are tunable in vivo by in
vitro selected binding proteins. Our approach could be of biopharmaceutical importance and might facilitate studies on
molecular mechanisms of ABC transporters.
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Introduction
In the past decade, unprecedented progress has been made in the
elucidation of ten complete ABC transporter structures solved by X-
ray crystallography, which guide current functional studies on these
transport proteins [1–5]. However, the mechanisms of transport of
both, ABC importers and exporters are still controversial [6]. One
reason for the uncertainties is due to the fact that crystal structures
represent snapshots of the proteins in specific conformations. In
order to describe the transport cycle in detail, several structures of
the same transporter captured in different conformational states
need to be solved. This often requires the trapping of the transport
protein in a specific conformational state which, for crystallized
primary-active transporters, was achieved by using non-hydrolyz-
able nucleotide analogs such as AMP-PNP [7,8] or various
nucleotide trapping agents such as vanadate, aluminium fluoride
and beryllium fluoride [9,10], or by generating mutant proteins that
are unable to hydrolyze ATP [11]. However, as these different
techniques interrupt the catalytic cycle of ATP hydrolysis at similar
stages, the repertoire of conformations that can be stabilized is
limited.
To overcome this limitation, we used designed ankyrin repeat
proteins (DARPins) which represent a novel binding scaffold [12].
DARPins typically consist of two or three internal ankyrin repeat
units encoding the randomized surface flanked by an N-terminal
and a C-terminal capping repeat [13,14]. DARPins are devoid of
disulfide bonds, easy to produce in E. coli and extraordinarily
robust [15]. High-affinity binders have been raised against a
growing number protein targets [16,17]. Amongst these is an AcrB
specific DARPin that was co-crystallized with AcrB to obtain the
highest resolution structure at 2.5 A˚ of this membrane protein to
date [18,19].
Traditionally, monoclonal antibodies (mAbs) specific for inte-
gral membrane proteins have been generated using the hybridoma
technology [20]. This procedure relies on the natural generation of
binders against the targeted protein in mice [21–26]. However, the
process of binder selection after the injection of the protein sample
into the animal is beyond experimental control. In vitro selections
using either phage display or ribosome display in contrast allow
binder selection under defined conditions [27,28]. Nevertheless,
the small number of less than ten published studies on the
complete in vitro selection of binders (Fab fragments and DARPins)
against detergent-purified membrane proteins embodies the
difficulties in using membrane proteins for this purpose [18,29–
36].
ABC transporters play a pivotal role in the active transport of
molecules in organisms of all kingdoms of life. The mammalian
multidrug transporter ABCB1 (also termed P-glycoprotein or
MDR1) has probably attracted most attention of all ABC
transporters, since it can play an important role in the extrusion
of noxious substances out of the cell, and has been linked to drug
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37845
resistance in tumor cells [37,38]. Prokaryotic homologues of
ABCB1 such as LmrA from Lactococcus lactis and MsbA from
Escherichia coli, and analogues such as LmrCD from L. lactis were
studied in detail and are involved in the transport of drugs, lipids
and small ions [39–45]. ABC transporters use the energy of ATP
binding and hydrolysis catalyzed by the nucleotide binding
domains (NBDs) to translocate substrates through the membrane
domain (MDs). For this purpose, the NBDs need to dimerize in a
sandwich-like fashion forming two composite catalytic sites [46].
The amino acids involved in ATP binding and hydrolysis are
encoded by a number of highly conserved sequence motifs
including Walker A, Walker B, ABC Signature and H-loop (for
review, see [2]).
In LmrCD, one of the two composite catalytic sites at the NBDs
deviates from the consensus sequence and is postulated to mediate
ATP binding, but not ATP hydrolysis [47]. The deviation from
the canonical sequence concerns the catalytically important
Walker B glutamate and H-loop histidine that are changed to
aspartate and glutamine, respectively. The same substitutions are
found in the non-canonical sites of the antigen peptide transporter
TAP1/2 and the yeast multidrug transporter Pdr5 [48,49]. Here,
we demonstrate the successful in vitro selection of binders against
detergent-solubilized LmrCD using ribosome display. Moreover,
we use the lactococcal cells for a novel in vivo functional screen
applicable for multidrug transporters, and we characterize the
functional consequences of DARPin binding to LmrCD.
Results
Selection of DARPins Against Detergent Solubilized
LmrCD
We cloned the lmrCD genes with a His10-tag N-terminally to
LmrC, and were able to purify functionally active LmrCD to
homogeneity from lactococcal membrane vesicles. The proteins
could be isolated as heterodimeric species from size exclusion
chromatography (SEC) columns (Figure S1A and B). Interestingly,
the heterodimeric complex of LmrCD was stable when the
purified protein was analyzed by nano-electrospray mass spec-
trometry [50]. In order to immobilize LmrCD during the DARPin
selection procedure, an Avi-tag was introduced C-terminally to
LmrD, which allowed for site-specific enzymatic biotinylation of a
lysine residue comprised within the Avi-tag sequence (biotinylated
LmrCD is denoted bLmrCDAviC) [51]. The DARPin selection was
performed using the ribosome display method with DARPins
including three internal randomized repeats (N3C DARPins)
(Figure 1A) [12,18,28]. A total of 4 sequential selection rounds
were performed in which catalytically active bLmrCDAviC and
orthovanadate-trapped bLmrCDAviC were used as two indepen-
dent protein formulations. In the presence of 1 mM ATP, LmrCD
could be trapped by orthovanadate with a concentration giving
half-maximal inhibition of ATP hydrolysis (IC50) of 120 mM which
is in agreement with a recent study on the heterodimeric ABC
transporter BmrCD [52] (data not shown). The orthovanadate
concentration (1 mM) used during the DARPin selections
comfortably exceeded this IC50. It should be noted that around
0.6 mM of ATP originating from the in vitro translation buffer and
around 40 mM magnesium acetate were present during the
incubation of the DARPins with the target protein. This means
that in case of the non-trapped bLmrCDAviC formulation, the
DARPins were selected against transporters slowly hydrolyzing
ATP and presumably adopting various conformational states.
Figure 1. Ribosome display and ELISA set-up. (A) Sketch
delineating one DARPin selection round using ribosome display
(adopted from [31]). The DARPin library in form of mRNA is in vitro
translated and stable ribosomal complexes linking the phenotype
(folded DARPins) with the genotype (translated mRNA) are generated.
The ribosomal complexes are allowed to bind to immobilized
bLmrCDAviC. After a washing step of variable length (depending on
selection stringency), bound ribosomal complexes are destabilized and
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Identification of LmrCD-specific DARPin Binders by ELISA
We analyzed 190 clones from the DARPin pools, enriched over
four selection rounds against untreated or vanadate-trapped
bLmrCDAviC, by an established ELISA protocol (95 DARPins
for each protein formulation) (Figure 1B, Figure 2) [31]. From the
initial ELISA (not shown) we chose the clones giving rise to the 30
most intense ELISA signals against bLmrCDAviC (15.8% of
examined clones) for a second comparative ELISA (Figure 3A).
Besides LmrCD, the ABC transporter MsbA and the secondary-
active multidrug transporter AcrB were used in the assay
(prepared as proteins biotinylated at the C-terminal Avi-tag).
From the 30 ELISA-positive DARPins, 8 were exclusively binding
to bLmrCDAviC but not to bMsbAAviC or bAcrBAviC (4.2% of all
examined clones), whereas the other 22 DARPins were promis-
cuously binding to all membrane proteins used in the specificity
ELISA (Figure 3A). The quality of the control proteins bMsbAAviC
and bAcrBAviC was confirmed by using target-specific DARPins in
the ELISA assay (AcrB-specific DARPin 110819 is described [18];
the selection of the MsbA-specific DARPin_55 will be published
elsewhere). The genes encoding the eight LmrCD-specific
DARPins were sub-cloned, expressed without the C-terminal
Myc5-tag and analyzed by size exclusion chromatography. Four of
these DARPins displayed a substantial degree of aggregation
(soluble aggregates) and were therefore excluded. The other four
LmrCD-specific DARPins (a-LmrCD#1-4) ran as monomeric or
dimeric species on SEC taking the elution profile of the
monomeric control DARPin E3_5 as a reference (Table 1, Figure
S1C). Three out of these four DARPins exhibited tight binding to
purified LmrCD, and eluted in complex with their target from the
size exclusion column. Thus, the initially chosen 190 DARPin
clones could be narrowed down to 3 specific high-affinity binders,
corresponding to a hit rate of 1.6%. A fifth high-affinity DARPin
(a-LmrCD#5) was found in another ELISA screen identical to the
one above (not shown).
Identification of Activators of LmrCD by Functional
Screening in L. Lactis
LmrCD-mediated daunomycin resistance in L. lactis [53] was
used for screening of DARPins that affect LmrCD activity.
Individual DARPins of the pool obtained after four selection
rounds (Figure 2; note: these are not the DARPin binders
identified by ELISA from the previous section) were expressed at
high levels in the cytoplasm of L. lactis using the nisin-inducible
lactococcal vector pNZ8048 (estimated to 2–5% of total soluble
protein, not shown) [54]. We first attempted to find DARPins
whose expression lead to a decrease of LmrCD-dependent
daunomycin resistance (inhibitors). Around 20 apparent inhibitors
were found by screening 400 DARPin clones expressed in L. lactis.
A closer inspection of these initial hits however, revealed that they
were false positives; lactococcal cells expressing these DARPins
grew considerably slower than cells expressing the control
DARPin E3_5*. When these DARPin inhibitors were expressed
in the L. lactis strain lacking the chromosomal lmrCD genes (L. lactis
NZ9000 DlmrA DlmrCD [55]), the apparent inhibition was also
observed. Hence, the increased drug susceptibility of L. lactis
expressing these DARPins was independent of LmrCD. Surpris-
ingly, we also found DARPins the expression of which increased
daunomycin resistance in L. lactis, suggesting enhancement of
LmrCD activity. Three strong activators (DARPin_Act1-3) were
found in a screen including 1128 clones (Figure 2). In cell growth
experiments, the daunomycin resistance of L. lactis NZ9000
expressing the activator DARPins was compared to the control
DARPin E3_5* in the wildtype and the DlmrCD background
(Figure 4A and B). In wildtype cells, the IC50 for daunomycin was
increased by a factor of 3.3, 2.6 and 1.7 upon the production of
DARPin_Act1, DARPin_Act2, and DARPin_Act3, respectively.
Importantly, the expression of the activator DARPins in the
L. lactis NZ9000 DlmrA DlmrCD background did not affect the
daunomycin resistance of the cells, indicating an LmrCD-specific
functional stimulation. The knock-out of lmrCD in L. lactis results in
an 8.3-fold decrease of the IC50 for daunomycin (Figure 4A and
B). Therefore, the DARPin-induced stimulation of LmrCD-
mediated drug transport by a factor up to 3.2 is substantial. The
DARPins a-LmrCD#1-5 that were identified in the ELISA screen
to bind to LmrCD (see previous section) were also assayed
regarding the potential modulation of the LmrCD-mediated drug
resistance in L. lactis. Although DARPins a-LmrCD#1-5, the
DARPin activators and DARPin E3_5* were overproduced
equally well in L. lactis, expression of DARPins a-LmrCD#1-5
did not alter the drug resistance of lactococcal cells towards
daunomycin (not shown).
Further Characterization of the LmrCD-activating
DARPins
The chromosomal knock-out of the lmrCD gene on L. lactis has
been shown to result in an increased susceptibility of the
lactococcal cells towards Hoechst 33342 (3.6 fold difference
between wiltype L. lactis and the DlmrCD mutant) [53]. We
therefore tested whether the DARPin_Act1 to Act3 are also
capable of increasing the LmrCD-mediated transport of Hoechst
33342. However, in contrast to the observations on daunomycin
resistance in L. lactis (Figure 4) the expression of the DARPin
activators did not increase the resistance towards Hoechst 33342
(not shown).
The observed LmrCD-associated daunomycin resistance in
L. lactis could be due to enhanced drug efflux by LmrCD.
However, as the entry of fluorescent daunomycin from the
aqueous buffer into cells followed by its intercalation in DNA
results in a minor quenching of total fluorescence, detection of
daunomycin transport by fluorescence spectroscopy is hampered
by a poor signal-to-noise ratio in the fluorescence data. In an
alternative assay, we studied the LmrCD-mediated transport of
non-fluorescent, hydrophobic 29,79-bis-(2-carboxyethyl)-5(6)-car-
boxyfluorescein acetoxymethyl ester (BCECF-AM), which is
extruded from the plasma membrane by bacterial and mammalian
multidrug ABC transporters before it can be hydrolyzed in the
cytoplasm into fluorescent BCECF by non-specific esterases [56–
58]. In this assay, a slower increase in the fluorescence signal is
associated with enhanced extrusion of BCECF-AM from the cell.
As BCECF is a pH-sensitive fluorophore, valinomycin and
nigericin were added to the cells prior to the transport
measurement to dissipate the electrochemical proton gradient
across the plasma membrane, so that the intracellular pH was
made equal to the constant pH of the extracellular buffer. In
agreement with the observations for daunomycin, increased
BCECF-AM efflux was observed upon expression of DARPi-
mRNA encoding for potential target-specific DARPins is liberated. The
eluted mRNA is amplified by reverse transcription and PCR to double
stranded DNA, which is in vitro transcribed into mRNA for another
round of selection or used for binder analysis. (B) Schematic drawing of
the ELISA set up. Protein A is coated onto the ELISA well and is
decorated with an anti-myc antibody that immobilizes the DARPins via
the C-terminal Myc5-tag. Upon binding of purified, biotinylated target
protein (e.g. LmrCD, AcrB or MsbA in our study) to DARPin, the target
protein is detected using a streptavidin-alkaline phosphatase the
activity of which was detected colourimetrically at OD405 using p-
nitrophenyl phosphate as a substrate.
doi:10.1371/journal.pone.0037845.g001
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n_Act2 in wildtype L. lactis, whereas DARPin_Act2 expression in
the lmrCD knockout-strain did not affect transport (Figure 4C).
Sequencing revealed that DARPin_Act1 lacked the N-terminal
cap repeat and therefore exhibited severe aggregation (but not
precipitation) in purified form as demonstrated in SEC experi-
Figure 2. Workflow of DARPin selection and screening. DARPins were selected by ribosome display against LmrCD with and without vanadate
trapping (purple rectangle). After four sequential selection rounds of increasing stringency, the pools of potential binders were analyzed either by
ELISA and SEC (blue rectangle) or in a functional screen in L. lactis (red rectangle).
doi:10.1371/journal.pone.0037845.g002
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Figure 3. Identification and characterization of DARPin binders by ELISA (A) Specificity ELISA using bLmrCDAviC, bMsbAAviC and bAcrBAviC
as target proteins. Seven DARPins (a-LmrCD#1-5, DARPin_Act2 and DARPin_Act3) were found to be highly specific for bLmrCDAviC. Many initial
DARPin binder-hits promiscuously bound to bLmrCDAviC, bMsbAAviC and bAcrBAviC as exemplified with the ‘‘unsp. DARPin’’ and were therefore not
useful for further analysis. DARPins specific for bMsbAAviC (DARPin_55) and bAcrBAviC (110819) were used as a positive control. (B) ELISA analyzing
LmrCD-Specific in vitro Selected DARPins
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ments (Table 1, Figure S1D). This impeded further biochemical
and biophysical characterization of DARPin_Act1. Although
DARPin_Act2 was of the expected N3C format, it was prone to
form soluble aggregates (hexamers), presumably due to a high
number of hydrophobic residues found in its randomized
positions. DARPin_Act3 predominantly existed as a monomer
and the aggregated species could successfully be removed by SEC.
Expression of LmrCD-activating DARPins does not
Increase the LmrCD Production Level
The observed gain of cellular drug resistance and enhanced
rates of substrate efflux in DARPin producing cells could be
explained if DARPin expression would upregulate the expression
level of LmrCD. In order to compare the amounts of expressed
LmrCD protein in the plasma membrane from DARPin-
producing and control cells, we introduced a V5-tag downstream
to the lmrD copy on the chromosome by homologous recombi-
nation. Cells producing the V5-tagged version of LmrD (LmrDV5)
were as resistant to daunomycin as the wildtype cells. A specific
band for LmrDV5 could be detected by Western blotting with an
anti-V5 antibody (Figure 5A). L. lactis NZ9000 lmrDV5 expressing
the activator DARPins and the control DARPin E3_5* were
grown in the absence of drug and in the presence of the
daunomycin concentration (see Materials and Methods). The
amount of LmrDV5 was then analyzed by Western blotting
whereas the total protein was quantified using SYPRO ruby
staining. The LmrDV5 production level was consistently increased
by a factor of around 1.5 upon the exposure to daunomycin
irrespective of the DARPin expressed (Figure 5B). However, the
activator DARPins did not lead to a significant increase in
LmrDV5 production compared to the control cells, indicating that
the DARPin activators directly stimulate the drug efflux activity of
existing transporters.
LmrCD-specific DARPins Bind to LmrD in a 1:1
Stoichiometry Covering at least Three Partially
Overlapping Epitopes
To gain further insights into the binding epitopes of the
LmrCD-specific DARPins, LmrC and LmrD were expressed
separately including GFP fused to the C-termini. The proteins
were purified by Ni2+-NTA chromatography, followed by
chemical biotinylation and size exclusion chromatography (Figure
S1E). Further, the isolated NBDs of LmrC and LmrD were
purified from E. coli. Whereas the expression of the NBD of LmrC
gave rise to soluble aggregates exclusively (which were not used for
further analysis), purification of the NBD of LmrD yielded (besides
soluble aggregates) monomeric protein that was enzymatically
biotinylated (bLmrD-NBDAviN) (Figure S1F). Binding of these
isolated parts of LmrCD to a-LmrCD#1-5 and the activator
DARPins was then tested in an ELISA (Figure 3B). All DARPins
were found to bind to the LmrD chain, but none of them
recognized the NBD of LmrD or the LmrC chain suggesting that
the epitope(s) are likely to be located at the membrane domain of
LmrD. Alternatively, the isolated NBD of LmrD might adopt a
conformation different to the one found in the full-length
transporter which might not be recognized by the DARPins or
the binding epitope covers a shared surface located on the MD
and the NBD of LmrD.
The binding epitopes were further analyzed in a competition
ELISA, in which bLmrCDAviC was pre-incubated with a tenfold
excess of each DARPin devoid of the Myc-tag and probed for
binding to every DARPinmyc5 immobilized via the Myc-tag
(Figure 6A). Based on the results of this competition ELISA, the
LmrCD-specific DARPins are proposed to bind to at least three
partially overlapping epitopes (Figure 6B). The first epitope
(epitope 1 of binders a-LmrCD#2 and a-LmrCD#4) and the
second epitope (epitope 2 of binders a-LmrCD#3 and a-
LmrCD#5) do not overlap (i.e. no competition for binding
between these two pairs of DARPins to LmrCD was observed). In
binding of the LmrCD-specific DARPins shown in (A) to LmrC (bLmrC-GFP), LmrD (bLmrD-GFP) and the nucleotide binding domain of LmrD (bLmrD-
NBDAviN). Binding to LmrCD (bLmrCDAviC) was confirmed as positive control.
doi:10.1371/journal.pone.0037845.g003
Table 1. Biophysical properties of LmrCD-specific DARPins.
DARPin Oligomeric state a)
Binding
stoichiometry
(DARPin: LmrCD) b) KD (nM)
c) ka (610
5 M21s21) c) kd (610
22 s21) c) KD, eq. (nM)
d)
Binders
a-LmrCD#1 Monomer 1.11: 1 10.0 7.40 0.738 10.7
a-LmrCD#2 Dimer/Trimer 0.96: 1 3.9 5.29 0.205 9.2
a-LmrCD#3 Monomer 0.73: 1 53.4 12.3 6.59 53.5
a-LmrCD#4 Monomer No complex 167 2.00 3.34 173
a-LmrCD#5 Monomer 0.75: 1 43.0 5.10 2.19 45.2
Activators
DARPin_Act1 Soluble aggregates n.d. e) n.d. n.d. n.d. n.d
DARPin_Act2 Hexamer n.d. e) 46.7 0.17 0.079 66.8
DARPin_Act3 Monomer 1.16: 1 50.5 4.36 2.20 54.9
a)Derived from elution volume of main peak on Superdex 200 10/300 GL column (Figure S1).
b)Determined by protein chip analysis (Figure 7B).
c)Values obtained by SRP analysis using a 1:1 binding model (Figure 7C).
d)Value obtained by SPR analysis using binding equilibrium data (Figure 7D).
e)Separation of the DARPin-LmrCD complex from DARPin aggregates was not possible on SEC (Figure S1).
doi:10.1371/journal.pone.0037845.t001
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contrast, binding of a-LmrCD#1 and the DARPin activators
(DARPin_Act2 and DARPin_Act3) to LmrCD is competed by
DARPins recognizing epitopes 1 and 2 as well as by themselves.
Hence the binding epitopes of a-LmrCD#1 and the DARPin
activators are suggested to partially overlap with the first two
epitopes. Nevertheless, conformational communication between
two well-separated sites resulting in apparent competition of
binding cannot be excluded. The presence of two distinct epitopes,
one for a-LmrCD#1 (epitope 3) and the other for activator
DARPins (epitope 4), is supported by the large differences in
sequence between a-LmrCD#1 and the activator DARPins
(Figure 6B, Figure S2). Trapping of LmrCD with vanadate did
not help to generate DARPins different from the ones selected in
the absence of trapping agent as DARPin a-LmrCD#2 (non-
vanadate DARPin) shares the epitope with a-LmrCD#4 (vana-
date DARPin), and a-LmrCD#5 (non-vanadate DARPin) shares
the epitope with a-LmrCD#3 (vanadate DARPin). Clearly,
‘‘vanadate’’ DARPins do not bind to a shared epitope that is
distinct from the epitope of the ‘‘non-vanadate’’ binders.
The stoichiometry of binding between the DARPins and
LmrCD after SEC was determined by protein chip technology
(Agilent Technologies) allowing accurate quantification of protein
amounts (Figure 7A and B, Table 1). DARPin_Act3 as well as a-
LmrCD#1, a-LmrCD#2, a-LmrCD#3 and a-LmrCD#5 form
1:1 complexes with LmrCD (Table 1). DARPin_Act1 and
DARPin_Act2 formed soluble aggregates impeding their separa-
tion from LmrCD on SEC whereas the affinity of a-LmrCD#4
appeared to be too low to allow co-elution with LmrCD from the
gel filtration column. Therefore, the stoichiometry of binding
could not be determined for these DARPins.
Determination of the Dissociation Constants by Surface
Plasmon Resonance (SPR)
The affinities of the isolated DARPins to LmrCD were
determined by SPR measurements using a Biacore instrument.
Detergent purified bLmrCDAviC was immobilized on a streptavi-
din-coated chip and binding of the DARPins was assessed
(Figure 7C and D, Table 1). When using a two-state reaction
model (see Materials and Methods), the observed data fitted very
close to the predicted data. However, to assess whether DARPin
binding to LmrCD is correctly described by a two-state reaction
model, 400 nM of a-LmrCD#3 was injected for 100 s, 200 s and
400 s, and DARPin dissociation phases were compared (Figure
S3). The dissociation curves obtained, superimposed almost
perfectly, suggesting that DARPin dissociation was independent
of the association time. These findings indicate that the use of the
two-state reaction model is inappropriate. Therefore, all data were
fitted using a simple 1:1 binding model (see Materials and
Methods), which allowed for the calculation of the dissociation
constants (KD) from the association and dissociation rate constants
ka and kd (Table 1). To determine equilibrium binding constants
(KD,eq., see Materials and Methods, Figure 7D and Table 1),
injection times were chosen that allowed DARPin binding to reach
equilibrium (Figure 7C). With the exception of a-LmrCD#2 and
DARPin_Act2, the KD and KD,eq. were found to be almost
identical. Since KD,eq. is unaffected by known SPR artifacts such as
mass transport and analyte rebinding [59], we refer to the KD,eq. to
describe the affinities of the DARPins for LmrCD in this study.
The KD,eq. values of the majority of LmrCD-specific DARPins
were between 9 nM and 67 nM with the exception of the KD,eq. of
173 nM for a-LmrCD#4. Confirming the SPR measurements, a-
LmrCD#4 binding to LmrCD was too weak for co-elution of the
protein complex during SEC (Table 1); the ELISA signal was
considerably lower than for the other binders (Figure 3A).
DARPin Binding to Membrane-embedded LmrCD
The binding of DARPins to inside-out membrane vesicles
(ISOVs) containing either overproduced AcrBAviC or LmrCDAviC
was further characterized (Figure 8). Based on an analysis using a
protease-cleavable LmrCD-GFP construct (see Materials and
Methods), ISOV preparations were found to contain up to 10%
of the membrane vesicles in the right-side-out orientation (right-
side-out membrane vesicles, RSOVs). Total binding was deter-
mined as the amount of DARPin bound to ISOVs containing the
Figure 4. Identification of LmrCD-activating DARPins. (A) Overexpression of DARPin_Act1 (N), DARPin_Act2 (#), DARPin_Act3 (.) in wildtype
L. lactis increases the resistance towards daunomycin compared to cells expressing control DARPin E3_5* (not interacting with LmrCD) (D). (B) No
differences were observed when experiments in (A) were performed with cells lacking the chromosomal copy of lmrCD. (C) BCECF-AM transport
measurements in pre-energized wildtype L. lactis cells demonstrate activation of LmrCD-mediated extrusion upon expression of DARPin_Act2 (trace
1) but not of control DARPin E3_5* (trace 2). No activation of LmrCD activity was observed upon expression of DARPin_Act2 (trace 3) or control
DARPin E3_5* (trace 4) in L. lactis DlmrCD cells. Shown are representative data from at least three independent measurements (n$3).
doi:10.1371/journal.pone.0037845.g004
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overexpressed target protein. Background binding refers to
binding of the respective DARPin to ISOVs containing an
overexpressed membrane protein that is not recognized by the
binder. For the AcrB-specific DARPin 110819, the membrane
vesicles used for the determination of background binding thus
contained overexpressed LmrCD and vice versa. Specific binding
was then calculated by subtracting background binding from total
binding. Binding of all six DARPins tested was target-specific,
meaning that total binding was stronger than background binding.
The AcrB-specific DARPin 110819, whose structure has been
solved in complex with AcrB by X-ray crystallography, was used
as control. As expected, DARPin 110819 binds relatively poorly to
ISOVs despite its high reported binding affinity of 28 nM because
the binding epitope on AcrB is located at the periplasmic loops
and is therefore predominantly hidden in the vesicle lumen [18].
The binding signal for DARPin 110819 therefore originates from
the estimated 10% RSOVs present in the ISOV preparation.
Despite the fact that AcrB is expressed better than LmrCD (not
shown), binding of a-LmrCD#2 and DARPin_Act3 to LmrCD-
containing ISOVs resulted in signals that were around three times
Figure 5. DARPin expression does not significantly alter expression of LmrCD proteins. (A, B) A V5-tag was introduced in frame at the 59-
end of genomic lmrD in L. lactis (denoted L. lactis NZ9000 lmrDV5). Plasmid-encoded DARPin activators or the control DARPin E3_5* were expressed in
L. lactis NZ9000 lmrDV5 in the presence and absence of daunomycin (14 mM for DARPin_Act3 and E3_5* and 28 mM for DARPin_Act1 and
DARPin_Act2, respectively). The expression levels of genomic LmrDV5 were then quantified by comparing the Western blot signal obtained using an
anti-V5 antibody (A) with total protein detected by SYPRO ruby staining (B). (C) The relative amounts of LmrDV5 expression were quantified by
densitometry. Each bar represents the average of three independent data points (n = 3) of which one data point is shown in (A) and (B).
doi:10.1371/journal.pone.0037845.g005
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bigger than the ones of DARPin 110819 binding to AcrB-
containing ISOVs (Figure 8A). Since the binding affinities of a-
LmrCD#2 (9 nM) and DARPin_Act3 (55 nM) are in the same
order of magnitude as of DARPin 110819 (28 nM), these LmrCD-
specific DARPins appear to recognize epitopes at the cytoplasmic
portion of LmrD, which are accessible in ISOVs. Specific binding
of a-LmrCD#1 on the other hand is half as high as for DARPin
110819 whereas it is roughly the same for a-LmrCD#3. DARPin
binding to these epitopes is therefore either restricted in
membrane-embedded LmrCD or the epitope is only accessible
from the physiological outside of the membrane. We also
attempted to perform these DARPin binding experiments using
RSOVs generated from E. coli using the EDTA-lysozyme method
[60]. Studies on the accessibility of a C-terminal GFP fusion
partner on LmrD to protease cleavage from the external surface of
membrane vesicles indicated that, despite careful preparations, a
substantial portion (up to 50%) of LmrCD-GFP containing
membrane vesicles were in the inside-out orientation, and that
Figure 6. Epitope mapping of LmrCD-specific DARPins by ELISA. (A) Analysis of the LmrCD-specific DARPins by a competition ELISA. Binding
of bLmrCDAviC to immobilized Myc-tagged DARPins was competed with an excess of DARPins devoid of Myc-tag. (B) Schematic drawing of the four
proposed binding epitopes on LmrCD recognized by the LmrCD-selective DARPins based on the results of the competition ELISA shown in (A). The
number of the epitopes follows the numbering in the main text. (C) The phylogenetic tree of the LmrCD-specific DARPins corresponds well with the
proposed binding epitopes. The branches of the phylogenetic tree are highlighted with the color code used to label the four suggested binding
epitopes in (B).
doi:10.1371/journal.pone.0037845.g006
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therefore, this type of membrane vesicles could not be used to
study the accessibility of the binding epitopes (data not shown).
Background binding to ISOVs varied between the different
DARPins and correlated with the aggregation behavior on SEC
(Figure S1). Low background binding was observed for the
DARPins a-LmrCD#1, a-LmrCD#3 and the AcrB-DARPin
110819, whereas a-LmrCD#2, DARPin_Act2 and DARPi-
n_Act3 interacted with membrane vesicles lacking the target
protein (Figure 8A).
Specific binding of DARPin_Act2 to LmrCD in ISOVs was low
in the initial binding experiment, most likely due to its slow on-rate
of binding (Figure 8A, Table 1). Therefore, binding of DARPi-
n_Act2 and a-LmrCD#3 to membrane-embedded LmrCD in
ISOVs was determined at a prolonged incubation time (200 min
instead of 40 min) and at increasing DARPin concentrations
(0.35 mM as in the initial experiment, 1 mM and 2 mM) (Figure 8B).
Although background binding of DARPin_Act2 remains high,
specific binding was substantially increased, in particular at a
DARPin concentration of 2 mM. For the DARPin a-LmrCD#3
on the other hand, background binding was very low and maximal
specific binding was achieved already at a concentration of 1 mM.
Taken together, these binding assays suggest that specific protein-
protein interactions between the activator DARPins and mem-
brane-embedded LmrCD are likely to provide the basis for the
activation of LmrCD-mediated drug transport, although indirect
mechanisms due to binding of the DARPin activators to the
membrane cannot be excluded. Binding of DARPin_Act2 and
DARPin_Act3 to LmrCD-containing ISOVs indicates that the
DARPin activators can bind to their epitope on LmrD when
expressed in the cytoplasm of L. lactis. If we assume a protein
concentration of 200 mg/ml in the cytoplasm of L. lactis [61] and
estimate the DARPin expression level to amount for 2% of total
protein (not shown), the DARPin concentration inside the cell is
about 4 mg/ml or 200 mM. The DARPin concentration in the cell
exceeds its binding affinities by more than three orders of
magnitude and therefore the binding epitopes are saturated with
bound DARPins.
DARPin Activators Stimulate the Basal ATPase Activity of
LmrCD Reconstituted in Proteoliposomes
To further elucidate the mechanism by which the DARPin
activators stimulate the function of LmrCD, detergent-purified
LmrCD was reconstituted into proteoliposomes made of polar
E. coli lipids and egg-phosphatidylcholine mixed at a ratio of 3:1
[55]. Reconstituted LmrCD exhibits basal ATPase activities that
are three times lower than the activity of purified LmrCD in its
micellar form (not shown). Addition of increasing concentrations
of daunomycin to reconstituted LmrCD (5–200 mM) increased its
ATPase activity in a dose-dependent manner, reaching two-fold
stimulation at 200 mM daunomycin (Figure 9A). The ATPase
activity of reconstituted LmrCD in the presence of the DARPin
activators and the control DARPin E3_5 was then compared to
samples to which no DARPins were added (Figure 9B). The
addition of DARPin E3_5 did not change the ATPase activity of
LmrCD at any concentration of daunomycin. On the other hand,
ATP hydrolysis of LmrCD was significantly stimulated upon
addition of the three DARPin activators up to 1.6 fold in case of
DARPin_Act2. These observations in proteoliposomes were found
to be statistically significant in three independent reconstitution
experiments, one of which is shown in Figure 9B. The DARPin
activators are therefore capable of increasing the ATPase activity
of LmrCD to a similar extent as 50 mM of daunomycin for which a
1.8 fold increase is seen (Figure 9A and B). The increase of
LmrCD’s ATPase activity by the DARPin activators and
daunomycin was found to be additive, suggesting that the
molecular mechanism underlying these stimulatory effects are
distinct. Basal and DARPin_Act2-stimulated ATPase activity of
reconstituted LmrCD was further elucidated over a range of ATP
concentrations (Figure 9C). The data was fitted using the Hill
equation, and the apparent Km for ATP and Vmax of the ATPase
reaction as well as the Hill coefficient were determined. The errors
represent standard errors of the parameters derived from
nonlinear regression analysis. In presence of DARPin_Act2, the
apparent affinity of LmrCD for ATP was not significantly altered
(Km,app of 0.8560.06 mM and 0.7360.09 mM for DARPin_Act2
and E3_5, respectively). Vmax on the other hand was doubled in
the presence of DARPin_Act2 (Vmax of 500622 nmol/min/mg of
protein versus 247619 nmol/min/mg of protein). The Hill
coefficient was found to be unaltered in presence of DARPin_Act2
(2.060.3 and 2.060.5 for DARPin_Act2 and E3_5, respectively).
The sigmoidal nature of the fitted curve suggests positive
cooperativity between the non-canonical and the consensus
composite catalytic site of LmrCD, a finding reminiscent of the
maltose transporter and the isolated NBDs of HlyB [62,63].
Discussion
The in vitro selection of binders against integral membrane
proteins using ribosomal display is very fast (2–3 weeks of lab work
under ideal circumstances) and the biochemical conditions can be
controlled. Nevertheless, only few successful examples of in vitro
selected binders specific for membrane protein have been
reported, most likely due to the many unknowns that exist
regarding enrichment of specific binders against these hydropho-
bic proteins [18,29–36]. In this work we have made important
progress in the screening procedure of DARPins raised against
membrane proteins. We found that successful in vitro selection
depends on two critical factors. Firstly, the quality of the target
protein preparation is crucially important for success. LmrCD has
proven to be a suitable target since it could be purified to near
homogeneity, was catalytically active and could be isolated as
heterodimeric species by SEC (Figure S1A and B). Secondly,
during DARPin identification it is important to introduce a cross-
specificity ELISA using a set of different membrane proteins.
Figure 7. Biophysical characterization of the DARPin-LmrCD complexes. (A, B) Stoichiometry analysis as exemplified by the LmrCD/a-
LmrCD#2 complex. (A) LmrCD and the LmrCD/a-LmrCD#2 complex were separated by SEC (Superdex 200 PC3.2/30, GE Healthcare) with a void
volume V0 = 0.85 ml and a total volume Vt = 2.4 ml. A fraction corresponding to heterodimeric LmrCD in complex with a-LmrCD#2 complex (red bar)
was subjected to protein chip analysis (lane 3, inset). LmrCD and the DARPin a-LmrCD#2 were also analyzed (lanes 1 and 2, inset). The peak at a
retention volume of 1.2 ml corresponds to aggregated LmrCD. (B) The peak area of the protein chip chromatogram corresponding to LmrCD and a-
LmrCD#2 of lane 3 in (A) were calibrated with dilution series of LmrCD and DARPin of known protein concentrations (not shown) and were used to
determine the stoichiometry of the LmrCD-DARPin complexes (Table 1). (C) Affinities of the DARPins to LmrCD were determined by surface plasmon
resonance as shown for a-LmrCD#3. The colored lines correspond to the measured traces at different DARPin concentrations, the fitted curves (1:1
binding model) are shown as black lines. (D) The steady state DARPin binding signals achieved at the end of the association phase shown in (C) were
plotted against the DARPin concentration and fitted using an equilibrium binding equation equivalent to the Michaelis-Menten equation. In this
analysis, equilibrium dissociation constants (KD, eq.) were generated.
doi:10.1371/journal.pone.0037845.g007
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Using optimally prepared LmrCD, we obtained a relatively large
number of DARPins (around 70%) that showed strong cross-
reactivity with MsbA and AcrB. Further analysis showed that
many of these unspecific DARPins formed soluble aggregates.
Both observations might relate to the hydrophobicity of the target
proteins, which can drive selection of hydrophobic binding
surfaces in DARPins that tend to aggregate in an aqueous
environment. Indeed, DARPin aggregation was not observed at all
when DARPins were selected against a soluble test protein (MBP)
using the same selection procedure (data not shown). On the other
hand, the highly specific DARPins were much less aggregation-
prone and about half of them were monomeric as judged from
comparing the SEC profiles of the DARPins under study with the
monomeric control DARPin E3_5 (Figure S1C). Because the
cross-specificity ELISA was performed with DARPin-containing
crude cell extracts, there was no need to purify the DARPins for
the initial specificity analysis, which greatly accelerated the
identification of binders. This screening regime would also be
applicable to more difficult membrane protein targets with a
further decreased binder hit rate.
A handful of the LmrCD-specific DARPin binders were
subsequently characterized by surface plasmon resonance and
size exclusion chromatography. With the exception of the
DARPin a-LmrCD#4, the KD,eq. values for binding were found
to range between 9 and 67 nM. The binding stoichiometry of
these high-affinity binders with heterodimeric LmrCD is 1:1. The
LmrCD-specific DARPins are suggested to recognize at least three
overlapping epitopes on the LmrD chain. The surface of LmrD
might therefore harbor one or several hot spot epitopes that are
preferably recognized by the DARPins. Recently, a hot spot
epitope that is recognized by nine highly diverse DARPins has
been reported for AcrB [19]. The fact that a handful of high
quality DARPins specific for LmrCD could be readily identified,
indicates that the randomized DARPin scaffold is sufficiently
diverse to recognize a multitude of binding sites on the membrane
protein target. Given the high binding affinities achieved and the
various epitopes recognized on LmrCD, these DARPins can be
Figure 8. DARPin binding to membrane-embedded LmrCD. (A) Six DARPins (each at a 350 nM concentration) specific for AcrB or LmrCD were
probed for binding to ISOVs containing either overproduced AcrBAviC or LmrCDAviC. Bound DARPins were detected on Western blot (left panel). The
signals of the DARPin-specific bands were quantified by densitometry (right panel). Total binding denotes the quantified amount of DARPin bound to
membrane vesicles containing overexpressed target protein. Background binding refers to binding to membrane vesicles containing overexpressed
LmrCDAviC in case of the AcrB DARPin 110819, or overexpressed AcrBAviC when LmrCD-specific DARPins were used. Specific binding was calculated by
subtracting background binding from total binding. (B) Binding of DARPin_Act2 and a-LmrCD#3 to ISOVs containing either overproduced AcrBAviC
or LmrCDAviC was further assessed using increasing concentrations of DARPin (0.35 mM, 1 mM and 2 mM) and analyzed by Western blot (left panel).
The data was quantified as in (A) (right panel). The data represent typical results observed in n = 3 experiments.
doi:10.1371/journal.pone.0037845.g008
LmrCD-Specific in vitro Selected DARPins
PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e37845
used for chaperone-assisted membrane protein crystallography
[64].
Binding experiments using LmrCD-containing ISOVs suggest
that the DARPins a-LmrCD#2 and DARPin_Act3 bind to
epitopes located at the cytoplasmic side of LmrCD. DARPin
activators expressed in the L. lactis cells are therefore expected to
readily reach their binding epitope in vivo. Since these DARPins
recognize full-length LmrD, but not the isolated NBD of LmrD, it
is likely that they bind to the cytoplasmic loops of the membrane
domain of LmrD. The other LmrCD-specific DARPins tested (a-
LmrCD#1 and a-LmrCD#3) were found to bind to membrane-
embedded LmrCD as well. However, the relatively weak binding
signals suggest that access to the binding epitopes is either partially
restricted by the lipid bilayer or that the binding epitope is only
accessible from the physiological outside of the cell, which is
hidden in the vesicle lumen of ISOVs. In the latter case, the
binding signal would originate from the approximate 10% of
RSOVs found in ISOV preparations.
The drug resistance phenotype in L. lactis associated with the
genomic expression of LmrCD was used to screen our pre-selected
DARPins for those that influence the functional properties of this
multidrug transporter. We observed the production of DARPins in
the cytoplasm of L. lactis with a relatively low toxicity compared to
expression in E. coli. Three homologous DARPins (DARPin_Act1,
Act_2, and Act3) were obtained, which enhance the LmrCD-
associated resistance to daunomycin and activate efflux of
BCECF-AM, but which, surprisingly, do not alter the resistance
to Hoechst 33342. This finding is reminiscent to a study on
ABCB1, in which small molecules were found to increase its
transport activity for some drugs whereas the transport of other
drugs was not affected or even decreased [65].
We considered the possibility of an increased LmrCD produc-
tion level in L. lactis in the presence of DARPin activators that
might act as folding chaperones. To test this hypothesis, a V5-tag
was introduced in frame with lmrD on the chromosome of L. lactis,
an approach that, to the best of our knowledge, was carried out for
the first time in this bacterium. With this tool it was demonstrated
that the expression of the activator DARPins in L. lactis does not
lead to changes in LmrCD production levels in the presence as
well as in the absence of daunomycin. As a proof of concept,
LmrCD expression was increased 1.5-fold in the presence of
daunomycin, which agrees well with RT-PCR experiments
detecting a transient two-fold increase of mRNA transcription
from lmrCD upon drug stimulation [66]. From this experiment we
concluded that the increased daunomycin resistance as well as the
enhanced BCECF-AM efflux originates from a direct stimulation
of the activity of LmrCD transporters as a consequence of
DARPin binding.
Figure 9. ATPase activity of reconstituted LmrCD is stimulated
by DARPin activators and daunomycin. Each symbol or bar
represents the average of three data points. (A) The ATPase activity of
reconstituted LmrCD is stimulated in the presence of daunomycin in a
dose-dependent manner. (B) Reconstituted LmrCD (protein:lipid ratio of
1:50, proteoliposomes diluted to obtain an LmrCD concentration of
70 nM) was incubated with DARPin activators and control DARPin
E3_5* (2.5 mM) and the ATPase activity was determined in the absence
and presence of 50 mM daunomycin (triplicates). As a control, buffer
instead of DARPins were added to LmrCD. According to t-test analysis,
the measured ATPase activity differences between DARPin_Act1 to Act3
and the buffer control are statistically significant (p,0.01 in the absence
and p,0.05 in the presence of daunomycin, respectively). (C) The
ATPase activities of LmrCD in the presence of DARPin_Act2 and E3_5
were determined over a range of ATP concentrations. The data points
were fitted to the Hill equation.
doi:10.1371/journal.pone.0037845.g009
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To gain more insight into the potential mechanism underlying
the activation of drug transport, the influence of the DARPin
activators on the ATPase activity of reconstituted LmrCD was
studied. The DARPin activators were found to stimulate the
ATPase activity of reconstituted LmrCD to a similar extent as
daunomycin applied at a concentration of 50 mM. Activation of
the basal ATPase activity of LmrCD upon DARPin expression is a
plausible explanation for the observed daunomycin resistance
increase in L. lactis. However, it cannot explain why the resistance
of lactococcal cells to Hoechst 33342 was not affected by the
expression of the DARPin activators. The exact mechanism
behind the modulation of LmrCD-mediated drug transport by the
DARPin activators is possibly much more complex. Recent studies
on Pdr5, a heterodimeric multidrug transporter of Saccharomyces
cerevisiae revealed a single mutation at one NBD which abolished
drug resistance against rhodamine-like compounds whereas
transport of other drugs was unaffected [67]. Likewise, a screen
identified small molecules dramatically altering the drug transport
profile of ABCB1 based on a molecular mechanism that remains
elusive [65]. These findings cannot yet be comprehensively
explained by current models of ABC transporter mechanism and
illustrate the limitation of our knowledge.
Beyond the activation of the basal ATPase by the DARPin
activators, we speculate that DARPin binding to LmrCD might
stabilize a conformational transition state at a rate-limiting step
during daunomycin and BCECF-AM transport. DARPin binding
could, for example, increase the overall rate of transport by
stabilizing the inward-facing state resulting in increased fractional
occupation during substrate binding, or enhance the dissociation
of the substrate from outward-facing LmrCD. But also the
resetting of LmrCD from the outward-facing to the inward-facing
state after ATP hydrolysis and drug release might be accelerated
by the DARPin activators. Finally, in addition to these possible
effects of DARPin binding on the maximal rate of efflux, DARPin
binding might directly influence the drug binding affinity of
LmrCD by imposing structural changes in drug binding surfaces.
The effect of DARPins on the mechanism of transport in in vitro
models (e.g. proteoliposomes) will be studied in future work.
In conclusion, we obtained three DARPins that activate
multidrug export by LmrCD in intact cells and stimulate the
ATPase activity of the transporter reconstituted into proteolipo-
somes. Our work demonstrates the potential of in vitro selected
artificial binding molecules to manipulate membrane transport
processes in vivo. Unlike chemical modulators, binding proteins
have the potential to stabilize any conformational (transition) state
of a membrane transporter, and offer the possibility to functionally
and structurally study membrane proteins in unprecedented ways.
When targeting membrane transporters associated with human
disease, DARPins could therefore be of great biopharmaceutical
importance.
Materials and Methods
Molecular Cloning and Expression of lmrCD and Other
Transporters
The primers and genetic constructs are listed in Table S1 and
Table S2. The lmrCD genes as well as the genes of msbA and acrB
were cloned with a coding region for an Avi-tag sequence at their
39-end, which allows the site-specific biotinylation of the target
proteins for the purpose of protein immobilization during
ribosome display and ELISA. A DNA fragment encoding the
Avi-tag sequence flanked by the restriction sites NheI and BamHI
was formed by annealing the two oligonucleotides avitag_for and
avitag_rev, and was ligated into the E. coli cloning vector pGEM
using the NcoI and XbaI restriction sites, yielding pGEM_Avi.
The lmrCD genes were amplified from the chromosome of
Lactococcus lactis subsp. cremoris MG1363 using the primers
lmrCD_DecaHisN_AviC_for for introduction of an N-terminal
His10-tag in LmrC and lmrCD_AviC_rev to add a C-terminal
Avi-tag to LmrD. The PCR product was cut with NcoI and XbaI
and cloned into the pGEM_Avi digested with NcoI and NheI
yielding pGEMLmrCDAviC. Two independent clones were
sequenced and were found to carry a nucleotide substitution
compared to the published sequence of Lactococcus lactis subsp.
cremoris MG1363 [68] at the triplet position of C179 in LmrC,
which is an arginine in our clone (TGC R CGC). In addition, a
construct lacking the C-terminal Avi-tag was cloned by amplifying
lmrCD from pGEMLmrCDAviC using the forward primer
lmrCD_NdeI_Presc_that introduces a linker and a prescission
protease cleavage site at the 59-end, and the reverse primer
lmrCD_rev. The PCR product was digested using NdeI/XbaI and
ligated into pGEMLmrCDAviC cut with the same enzymes,
resulting in plasmid pGEMLmrCD. The tagged lmrCD genes
were then sub-cloned via NcoI/XbaI either into the lactococcal
pNZ8048 vector [54] or the Escherichia coli expression vector
pBAD24 [69] yielding the expression vectors pNZLmrCDAviC,
pNZLmrCD, pBADLmrCDAviC and pBADLmrCD, respectively.
The msbA gene was cloned into pGEM_Avi via the restriction sites
NcoI/NheI amplifying the msbA gene with the primers msbA_-
DecaHisN_for and msbA_AviC_rev from the clone pNZMsbA
[44] yielding pGEMMsbAAviC. The gene of acrB from E. coli
devoid of NcoI sites (Murakami and van Veen, unpublished) was
amplified with the primers acrB_HisC_AviC_for and acrB_His-
C_AviC_rev and cloned via NcoI/NheI into pGEM_AviC
yielding pGEMAcrBAviC. The tagged msbA and acrB genes were
sub-cloned into pBAD24 using the restriction sites NcoI and XbaI
resulting in pBADMsbAAviC and pBADAcrBAviC. All sequences
were confirmed by DNA sequencing. The genes coding for lmrC,
lmrD and lmrCD were also cloned in frame with a C-terminal GFP
(that is cleavable by 3C protease) into pBAD24 applying the
recently developed FX-cloning method [70]. Similarly, coding
regions of the NBDs of LmrC and LmrD (which includes residues
G336 to D579 and G424 to E664 of LmrC and LmrD,
respectively) were cloned into a FX-vector adding a His10-tag, a
3C protease cleavage site and an Avi-tag to the 59-end of the
cloned genes (Geertsma and Dutzler, unpublished). The Walker B
glutamate of the consensus ATPase site of LmrCD was mutated to
glutamine using a quick-change standard protocol
(LmrD_E587Q). LmrCD protein containing a C-terminal Avi-
tag (LmrCDAviC) was produced in and purified from L. lactis
NZ9000 DlmrA DlmrCD [55] following published protocols [45,71].
The enzymatic site-specific biotinylation of the Avi-tag was carried
out in vitro using purified BirA yielding biotinylated LmrCDAviC
(bLmrCDAviC) [51], which was then used for DARPin selection
and ELISA. MsbAAviC and AcrBAviC were expressed in E. coli
harboring the corresponding pBAD24 expression vectors and were
purified and biotinylated accordingly.
DARPin Selection
The N3C DARPin library was chosen to select binders against
biotinylated LmrCDAviC (bLmrCDAviC) using the ribosome
display method [12,28,72]. In all selection rounds, 0.03% DDM
was used as detergent instead of the commonly used Tween-20 in
the standard ribosome display buffer WBT-BSA, containing
50 mM Tris-acetate pH 7.5, 150 mM NaCl, 50 mM MgOAc,
and 0.5% BSA. For the DARPin selection against vanadate-
trapped bLmrCDAviC, the protein was incubated with 1 mM ATP
and 1 mM Na3VO4 (freshly boiled as 100 mM stock, pH 9–10)
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prior to (1 h on ice) and during the incubation with the ribosomal
complexes. For the first three rounds, the selection was carried out
using the surface panning method by immobilizing bLmrCDAviC
via neutravidin on a solid support as described in the protocol of
Zahnd et al. [72]. The washing times before mRNA elution, were
set to 5, 2615 and 2630 min in the first, the second and the third
selection round, respectively. The fourth selection round was
carried out with the solution panning method [31]. 60 nM of
bLmrCDAviC was added to the stabilized DARPin in vitro
translation mixture (260 ml) and panned for 90 min. Streptavi-
din-coated magnetic beads (20 ml suspension Dynabeads MyOne
Streptavidin T1, Invitrogen) were used to capture the biotinylated
bLmrCDAviC with bound ribosomal complexes during 15 min.
The beads were rinsed twice with 300 ml WBT-BSA containing
0.03% b-DDM (WBT-BSA-DDM), placed into a fresh tube, and
washed for 30 min. After another tube change and another
30 min of washing, the mRNA was eluted and purified according
to the standard protocol [72].
Crude Cell Extracts and ELISA
The pools of DARPins from the 4th selection round were
expressed from the vector pQE30myc5 [31] in E. coli XL-1 Blue
yielding DARPins carrying an N-terminal RGS-His6 tag (with the
protein sequence MRGSHHHHHH) and a C-terminal Myc5-tag
(with five times the sequence MEQKLISEEDLNE). DARPin-
containing crude cell extracts were used to identify LmrCD-
specific binders by ELISA as described [31]. The DNA sequences
of all identified DARPins have been deposited in GenBank under
the accession numbers JQ425604-JQ425611.
SEC of Isolated DARPins and the LmrCD-DARPin
Complexes
The Myc5-tag fusion with the DARPins leads to the formation
of higher oligomeric species (not shown), and the DARPins were
therefore sub-cloned into the pQE30 vector (Qiagen) devoid of a
Myc-tag for further analysis and purified via Ni2+-NTA chroma-
tography and SEC (Superdex 200 10/300 GL, GE Healthcare)
according to standard procedures [14]. For the quantification of
the stoichiometric compositions of the LmrCD-DARPin complex-
es, Ni2+-NTA purified LmrCD (10 mM) was mixed with a twofold
excess of freshly gel-filtrated DARPin and incubated for 30 min.
The protein mixture was separated by SEC (Superdex 200 PC3.2/
30, GE Healthcare), after which fractions were analyzed by on-
chip protein analysis according to the manufacturer’s protocol
(Protein 80 Kit, Agilent Technologies).
Surface Plasmon Resonance
The affinities of selected DARPins towards detergent purified
bLmrCDAviC were determined by surface plasmon resonance on
a Biacore T100 machine (GE Healthcare). Because initial SRP
measurements in a buffer containing 0.03% DDM were difficult
to interpret, the dissociation constants were determined in the
presence of Tween-20 instead. To test the stability of LmrCD in
Tween-20, DDM was replaced with highly pure Tween-20
(Anapoe-20, 0.05%, Anatrace) in the washing and elution step
during LmrCD purification by Ni2+-NTA chromatography.
LmrCD purified using Tween-20 exhibited an ATPase activity
of 297624 nmol/min/mg of protein and its SEC elution profile
was indistinguishable from the one obtained with DDM (not
shown). For the SRP measurement, the detergent was changed
from DDM to Tween-20 after the immobilization of bLmrCDA-
viC on the Biacore chip, which lead to highly accurate and
undisturbed measurements. The target protein was purified
freshly as described above and 600 response units (RU) were
immobilized in flow cell 2 of a streptavidin-coated SA chip (GE
Healthcare), whereas flow cell 1 was used for referencing.
Affinities were determined in 20 mM Tris/HCl pH 7.5,
150 mM NaCl containing 0.05% (v/v) Tween-20 at 10uC and
a flow rate of 20 ml/min. The DARPin concentration was
determined by OD280 using a NanoDrop1000 Photospectrometer
and calculated based on theoretical extinction coefficients (www.
expasy.ch/tools/protparam.html). For each DARPin, a 3-fold
dilution series of six different concentrations were used for the
kinetic measurements (concentration ranges: 0.1 nM–72.9 nM
for a-LmrCD#1, a-LmrCD#2; 0.3 nM –218.7 nM for a-
LmrCD#3, a-LmrCD#5 and DARPin_Act3; 1 nM –729 nM
for a-LmrCD#4; 3 nM - 2187 nM for DARPin_Act2). Every
DARPin concentration was injected twice starting with the lowest
concentration, increasing to the maximal concentration and then
decreasing back to the lowest concentration. The association and
dissociation phases were set as follows (the first number denotes
association time/the second number denotes dissociation time):
a-LmrCD#1, a-LmrCD#2 and DARPin_Act2 (700 s/2400 s);
a-LmrCD#3 (240 s/1000 s); a-LmrCD#4, a-LmrCD#5 and
DARPin_Act3 (400 s/1200 s). The data were best fitted using a
two-state reaction model. This model assumes that the DARPin
(A) and LmrCD (B) form an initial complex (AB) with an
association rate constant ka1 (in M
21 s21) and a dissociation rate
constant kd1 (in s
21). This initial complex (AB) is then converted
into an alternative complex (AB*) with the association rate
constant ka2 (in s
21) and a dissociation rate constant kd2 (in s
21).
In this model, the dissociation constant KD (M) is calculated using
the following equation:
KD~
kd1
ka2
: kd2
(kd2zka2)
However, a control experiment in which a saturating concen-
tration of a DARPin was injected for varying times revealed, that
the two-state reaction model is inappropriate (see Results and
Figure S3). Therefore, the data were fitted using a simple 1:1
binding model and the dissociation constant KD was calculated
using the following equation in which ka is the association rate
constant and kd the dissociation rate constant:
KD~
kd
ka
In addition, the steady-state response units at the end of each
injection (i.e. when association and dissociation are in equilibrium)
were plotted against the injected DARPin concentration
(Figure 7D). The equilibrium constant KD,eq. was determined by
non-linear regression using an equilibrium binding equation
equivalent to the Michaelis-Menten equation in which R denotes
the SPR response at equilibrium, Rmax denotes the maximal SPR
response and [DARPin] is the DARPin concentration:
R~
Rmax DARPin½ 
KD,eq:z DARPin½ 
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Functional Screening in L. lactis
The control DARPin E3_5 [14] was cloned into the lactococcal
vector pNZ8048 from which it was expressed in L. lactis. During
the course of the study, DNA sequencing of the pNZ8048 clone of
the control DARPin E3_5 revealed the replacement of the second
repeat with the duplicated sequence of the third repeat in a
recombination event. This variant of E3_5 (E3_5*) was mono-
meric (not shown) and was used as control DARPin in the
functional experiments in L. lactis. For the functional screening of
the DARPins in L. lactis, the DARPin pools of the 4th selection
round were expressed from pNZ8048 in the presence of nisin A
(10 ng/ml) and daunomycin (10 mM or 18 mM to screen for
inhibitors or activators, respectively). The plasmids encoding for
potential inhibitory or activating DARPins were isolated, se-
quenced and retransformed into wildtype L. lactis NZ9000 and
L. lactis NZ9000 DlmrA DlmrCD. Resistance towards daunomycin
and Hoechst 33342 was determined by growing the cells at various
drug concentrations. A pre-culture devoid of nisin (150 ml) was
inoculated 1:100 with an overnight culture, after which cells were
grown for 210 min. The preculture was then diluted 1:100 into
medium containing 10 ng/ml nisin after which daunomycin was
added to various concentrations, and growth of cells was allowed
for 15 to 18 h. Final OD660 were measured and normalized by
setting the final OD660 reached in the absence of drug to 100.
Normalized values were plotted versus the daunomycin concen-
tration. The curves were fitted with a 4-parameter sigmoidal
equation in which y stands for the normalized final OD660, y0
describes the background OD660, x stands for the daunomycin
concentration, x0 is the inflection point of the curve, and a and b
are fitting parameters (SigmaPlot 10, default settings).
y~y0z
a
1ze
{(
x{x0
b
)
IC50 for daunomycin was defined as the daunomycin concen-
tration at which the OD660 after growth for 15–18 h is half as high
as in the absence of the drug.
Transport Assay with BCECF-AM
L. lactis NZ9000 and L. lactis NZ9000 DlmrA DlmrCD harboring
the expression plasmids for DARPin_Act2 and the unselected
DARPin E3_5* were grown to an OD660 of 0.6 and induced for
2 h with 5 ng/ml nisin A. Cells were harvested and washed twice
with ice-cold fluorescence buffer (50 mM potassium phosphate
pH 7.0, 5 mM MgSO4). For the fluorescence measurements, the
OD660 was adjusted to 0.5 and the cells were pre-energized by the
addition of 0.5% glucose whilst stirring. Nigericin and valinomycin
(1 mM each) were added prior to the addition of the fluorescent
substrate. Non-fluorescent BCECF-AM was added at a final
concentration of 0.2 mM. Subsequently, the formation of the
fluorescent BCECF was monitored at excitation and emission
wavelengths of 502 nm and 525 nm, respectively using slit widths
of 2.5 nm and 4 nm, respectively.
Quantification of LmrCD Production Levels in L. lactis by
the Introduction of a V5-tag
The sequence of the V5 tag (with the protein sequence
GKPIPNPLLGLDST) was introduced in frame with the genomic
lmrD gene at its 39-end in L. lactis using the Campbell-type
recombination method [73]. The DNA sequence of the V5 tag
containing the appropriate sticky overhangs was generated by
annealing the oligonucleotides V5-tag_for and V5-tag_rev and
cloned as double-stranded DNA fragment into pGEM_Avi cut with
BamHI/NheI yielding pGEM_V5 and thereby replacing the Avi-
tag sequence. An 860 bp stretch of chromosomal DNA downstream
to the lmrD gene was amplified with the primers lmrD_V5_for1 and
lmrD_V5_rev1 and introduced into pGEM_V5 using the restriction
sites BamHI/XbaI resulting in pGEMLmrCDV5*. The last 1583 bp
of lmrD were amplified with the primers lmrD_V5_for2 and
lmrD_AviC_rev, cut with NcoI/XbaI and cloned in frame with
the V5 tag sequence into pGEMLmrCDV5* cut with NcoI/NheI
yielding pGEMLmrDV5. The DNA fragment on pGEMLmrDV5
containing the V5 tag sequence flanked by a part of lmrD and a
stretch of DNA downstream of the lmrD gene on the L. lactis
chromosome was sub-cloned into pORI280 via NcoI/XbaI and
transformed into E. coli EC1000 (repA+) resulting in the plasmid
pORI280LmrDV5 [73,74]. Wildtype L. lactis NZ9000 was trans-
formed with pORI280LmrDV5 as described [55] yielding three blue
colonies after 3 days of incubation at RT. PCR analysis of the
chromosomal DNA revealed that two of these clones were the result
of the Campbell-type integration of pORI280LmrDV5. The second
recombination step was performed by growing a positive clone for a
total of 50 cell divisions in the absence of erythromycin and the
subsequent screening for white colonies on M17 agar plates. Two
white colonies were found (out of around 4000 colonies screened)
and confirmed to encode the lmrD gene fused with the V5 tag
sequence by Western blotting. This new strain was named L. lactis
NZ9000 lmrDV5. The plasmids encoding the activator DARPins and
the control DARPin E3_5* were transformed into L. lactis NZ9000
lmrDV5. A 1:100 inoculated preculture of transformed cells was
grown for 210 min in M17, 0.5% maltose, 5 mg/ml chloramphen-
icol and 50 ml thereof were used to inoculate 5 ml of the same
medium containing 10 ng/ml nisin with or without daunomycin
addition (14 mM for DARPin_Act3 and E3_5* and 28 mM for
DARPin_Act1 and DARPin_Act2, respectively). Each sample was
prepared in triplicates. The cultures were grown for 15 h and
harvested by centrifugation. Cells were resuspended in 350 ml of
50 mM Na-HEPES (pH 7), 1 mM MgSO4, 10% (wt/v) glycerol,
1 mM PMSF, 25 mg/ml DNaseI and trace amounts of lysozyme.
After the addition of glass beads (300 mg, 0.1-mm diameter),
samples were disrupted in a FastPrep device (MP Fastprep-24, MB
Biomedicals) twice for 30 s at force 6.5. Cell membranes were
harvested by centrifugation (55000 g) resuspended by SDS-PAGE
loading dye and the proteins were separated on a 10% tricine gel
[75]. Each sample was analyzed on two SDS-PAGE gels, one
dedicated to Western blotting and the other to the analysis of the
protein amounts with SYPRO ruby staining (a total of 6 gels due to
the triplicates). For the Western blotting analysis, the gels were
blotted onto a nitrocellulose membrane (wet blotting) and blocked in
TBST (TBS containing 0.1% Tween-20) supplied with 5% milk
powder overnight. The anti-V5 antibody (Sigma, clone V5-10,
1:3000 diluted in TBST) was panned for 160 min and the
membrane was washed three times for 10 min with TBST. After
incubation with a secondary anti-mouse HRP antibody (Jackson
ImmunoResearch Laboratories, 1:2500 in TBST) and another
three washing steps, the Western blot signal was detected with a
LAS-3000 imaging system (Fujifilm) using ECL reagent (PIERCE).
The second SDS-PAGE gel corresponding to the samples analyzed
by Western blot was stained with SYPRO ruby staining (Invitrogen)
and the fluorescent signal was read with the LAS-3000 imaging
system. The Western blots and the ruby-stained gels were quantified
using the Aida software (Raytest). The data were normalized by
setting the LmrDV5 level determined in cells expressing the control
DARPin in the absence of drugs to 1. The standard deviations of the
triplicates were calculated.
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DARPin Binding to Membrane Inserted Target Protein in
ISOVs
For the production of membrane vesicles, LmrCDAviC and
AcrBAviC were overproduced in E. coli C43 (DE3). Inside-out
membrane vesicles (ISOVs) were obtained after cell disruption at
20000 psi (Constant Systems). ISOVs containing overexpressed
LmrCD-GFP were prepared to determine the membrane vesicle
orientation by cleaving off the GFP at the external side using 3C
protease, followed by SDS-PAGE and quantification of the
cleavage reaction using in-gel fluorescence of remaining LmrCD-
GFP and cleaved GFP. Based on these experiments, ISOV
preparations contained 10% or less membrane vesicles of the
opposite (right-side-out) orientation. The membrane vesicles were
diluted at a protein concentration of 0.2 mg/ml in 1 ml of TBS,
pH 7.4. In a first set of experiments (Figure 8A) DARPins
(350 nM) were allowed to bind for 40 min to the ISOVs. In a
second set of experiments (Figure 8B), the DARPin_Act2 and a-
LmrCD#3 used at concentrations of 0.35 mM, 1 mM and 2 mM
were allowed to bind for 200 min. The membranes were
harvested by centrifugation for 20 min at 55000 g. The pellets
were resuspended with 800 ml of TBS to wash off unbound
DARPins, spun again, after which the pellets were resuspended
with SDS-PAGE loading dye (40 ml). Total membrane proteins
in membrane vesicles, and bound DARPins, were separated by
SDS-PAGE using tricine gels [75] and blotted onto nitrocellulose
membranes. The protein mixture was separated by SDS-PAGE
[75] and the bound DARPins were quantified by Western
blotting using RGS-His antibody (Qiagen) and detection by ECL
(PIERCE).
Reconstitution of LmrCD and ATPase Activity Assay
Ni2+-NTA-purified LmrCD expressed in L. lactis was reconsti-
tuted at a protein:lipid ratio of 1:50 (w/w) into acetone-washed
and ether-extracted total E. coli lipids mixed with egg phospha-
tidylcholine (Avanti) in a ratio 3:1 (w/w) in 50 mM K-HEPES
pH 7.0 following published protocols [41,76]. Where indicated,
SEC-purified DARPins (2.5 mM) were added to the proteolipo-
somes and incubated in 50 mM K-HEPES pH 7 for 12 h.
Daunomycin (where indicated) and MgSO4 (10 mM) were added
shortly prior to the assay start. The ATPase assay was performed
in 96-well PCR plates on the heating block of a PCR machine.
40 ml of reconstituted LmrCD (70 nM, including DARPins and
daunomycin where appropriate) was added to 10 ml of 5-fold stock
of highly pure ATP solution (SigmaUltra, 1 mM final concentra-
tion if not stated otherwise, dissolved in ddH2O adjusted to pH 7
using KOH) whilst the temperature was set to 4uC. The ATP
hydrolysis reaction was initiated by changing the temperature to
30uC for 20 min and stopped by denaturing the samples at 80uC
for 30 s. LmrCD mutated at the Walker B glutamate of the
consensus composite ATPase site (LmrD_E587Q) was reconsti-
tuted and used for background subtractions. This mutation was
shown previously and confirmed by us to be incapable of
hydrolyzing ATP [47]. The amount of generated Pi was quantified
colorimetrically using the malachite green/molybdate method
[55]. The datapoints of the ATPase activities measured at
increasing ATP concentrations (Figure 9C) were fitted with the 3
parameter Hill equation (Sigmaplot 10, default settings), in which y
denotes the ATPase activity, x stands for the concentration of
ATP, a corresponds to Vmax, b denotes the Hill coefficient, and c
corresponds to Km,app.
y~
axb
cbzxb
Data Analysis
Statistical analyses were performed with the Student’s t-test with
a 95% confidence interval for the sample mean. If not stated
otherwise, error bars represent the standard deviation (SD).
Supporting Information
Figure S1 Preparation of biotinylated target proteins
for the DARPin selections and ELISAs, and character-
ization of selected DARPins by SEC. (A) SDS-PAGE analysis
of purified LmrCDAviC. The protein bands corresponding to
overproduced LmrCDAviC are apparent in the total detergent-
solubilized membrane fraction (lane 1). Pure protein is eluted from
the Ni2+-NTA column (lane 2). (B) Ni2+-NTA purified LmrCDAviC
shown in (A) was in vitro biotinylated and separated by SEC to
remove aggregated protein and excess biotin. Fractions of the peak
at 12.50 ml corresponding to heterodimeric bLmrCDAviC were
used for the DARPin selections and ELISA (red bar). The strong
peak at the void volume of the column (9 ml) besides aggregated
LmrCD also contained genomic DNA that escaped from DNaseI
treatment (as evidenced by the strong A254 signal relative to the
A280 signal). (C, D), Gel filtration profiles of studied DARPins on
Superdex 200 column. The maxima of the main peaks were as
follows: (C) a-LmrCD#1:16.84 ml; a-LmrCD#2:15.11 ml; a-
LmrCD#3:16.37 ml; LmrCD#4:16.80 ml; a-
LmrCD#5:17.01 ml; E3_5:16.89 ml (D) DARPin_Act1:10.32 ml;
DARPin_Act2:13.25 ml; DARPin_Act3:16.38 ml. (E, F), SEC
profiles of LmrC-GFP and LmrD-GFP (E) as well as of LmrD-
NBDAviN (F). The fractions indicated by the red bar were used for
the ELISA shown in Figure 3B.
(TIF)
Figure S2 Sequence alignment of the LmrCD-specific
DARPins identified in this study. The sequence of the
consensus designed DARPin framework is given in the top line,
where ‘‘x’’ stands for all amino acids except proline, glycine and
cysteine and ‘‘y’’ stands for histidine, glutamine or tyrosine.
(TIF)
Figure S3 SPR control experiment disfavors a two-state
reaction model of DARPin binding to LmrCD. The fits of
the SPR sensograms were found to match better using a two-state
reaction model instead of a 1:1 binding model (see Materials and
Methods). To test whether the two-state reaction model was
appropriate for fitting, a saturating concentration of a-LmrCD#3
(400 nM) was injected onto a SPR SA-chip containing 600 RU of
immobilized bLmrCDAviC for 100 s, 200 s and 400 s (each
injection was performed twice). The traces were superimposed at
the starting point of the dissociation curve. DARPin dissociation is
virtually identical irrespective of the duration of association time,
indicating that the two-state reaction model is not appropriate.
Therefore, all SPR data were fitted using a 1:1 binding model
(Figure 7C and Table 1).
(TIF)
Table S1 Primers used in this study.
(DOC)
Table S2 Genetic constructs used in this study.
(DOC)
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